4 - KalVista Pharmaceuticals, Inc. (0001348911) (Issuer)

4 - KalVista Pharmaceuticals, Inc. (0001348911) (Issuer)

4 - KalVista Pharmaceuticals, Inc. (0001348911) (Issuer)

4 - KalVista Pharmaceuticals, Inc. (0001348911) (Issuer)

4 - KalVista Pharmaceuticals, Inc. (0001348911) (Issuer)

4 - KalVista Pharmaceuticals, Inc. (0001348911) (Issuer)

4 - KalVista Pharmaceuticals, Inc. (0001348911) (Issuer)

4 - KalVista Pharmaceuticals, Inc. (0001348911) (Issuer)

4 - KalVista Pharmaceuticals, Inc. (0001348911) (Issuer)

4 - KalVista Pharmaceuticals, Inc. (0001348911) (Issuer)

424B5 - KalVista Pharmaceuticals, Inc. (0001348911) (Filer)

10-K - KalVista Pharmaceuticals, Inc. (0001348911) (Filer)

8-K - KalVista Pharmaceuticals, Inc. (0001348911) (Filer)

8-K - KalVista Pharmaceuticals, Inc. (0001348911) (Filer)

SCHEDULE 13G/A - KalVista Pharmaceuticals, Inc. (0001348911) (Subject)

8-K - KalVista Pharmaceuticals, Inc. (0001348911) (Filer)

8-K - KalVista Pharmaceuticals, Inc. (0001348911) (Filer)

8-K - KalVista Pharmaceuticals, Inc. (0001348911) (Filer)

8-K - KalVista Pharmaceuticals, Inc. (0001348911) (Filer)

10-Q - KalVista Pharmaceuticals, Inc. (0001348911) (Filer)

– Received FDA approval of EKTERLY® (sebetralstat)—the first and only oral on-demand treatment for hereditary angioedema; U.S. launch underway – – Six additional global regulatory submissions under review – – Entered licensing agreements for sebetralstat commercialization in Japan and Canada – – $220.6M in cash, providing runway into 2027 – KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), today provided an operational update and released financial results for the fiscal year ended April 30, 2025. "The FDA approval of EKTERLY represents a major milestone—not only as the first commercial product for KalVista, but more importantly, as the first and only oral on-demand therapy for people

First new on-demand HAE treatment in over a decade, with potential to transform management of the disease Data demonstrated rapid symptom relief and attack resolution regardless of attack severity, location, age, or use of long-term prophylaxis, and well-established safety profile Management to host conference call today at 8:30 a.m. ET KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) today announced that the U.S. Food and Drug Administration (FDA) has approved EKTERLY® (sebetralstat), a novel plasma kallikrein inhibitor, for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged 12 years and older. EKTERLY is the first and only oral on-demand t

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), today announced that the compensation committee of KalVista's board of directors granted five newly-hired employees inducement options to purchase an aggregate of 23,000 shares of KalVista common stock on July 1, 2025 as inducements material to each employee entering into employment with KalVista. The options have an exercise price that is equal to the closing price of KalVista common stock on the grant date. One-fourth of the options vest on the one-year anniversary of the vesting commencement date and the remainder vest in equal monthly installments over the next three years, in each case subject to the new employee's continued service with

MONTREAL, June 26, 2025 /CNW/ - Pendopharm®, a division of Pharmascience Inc., has entered into an exclusive distribution agreement with KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a global biopharmaceutical company focused on the development of novel oral treatments for rare diseases. This agreement grants Pendopharm® the rights to manage regulatory approval and commercialization of sebetralstat, an investigational oral therapy for Hereditary Angioedema (HAE), developed by KalVista® in Canada. Financial details of the agreement remain confidential. Sebetralstat is poised to

-Sebetralstat has potential to become first oral on-demand treatment for HAE in Canada- -Pendopharm brings proven track record in commercializing innovative therapies across multiple therapeutic areas with capabilities to launch sebetralstat in Canadian market- KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) today announced that its wholly-owned subsidiary, KalVista Pharmaceuticals, Ltd., has granted Pendopharm, a division of Pharmascience Inc., the exclusive rights to manage the regulatory approval process and commercialization of sebetralstat in Canada. Sebetralstat is an investigational, oral on-demand treatment for hereditary angioedema (HAE). "We look forward to collaborating with P

–Real-world data highlight significant challenges with LTP adherence, and ongoing reliance on on-demand medications– –In KONFIDENT-S, oral sebetralstat delivered rapid, consistent relief for breakthrough attacks, regardless of long-term prophylaxis mechanism of action– KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) today announced the presentation of new data at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025 in Glasgow, United Kingdom that underscores the critical role of effective on-demand (OD) treatment for HAE attacks among patients receiving long-term prophylaxis (LTP). Sebetralstat for Treatment of HAE Attacks in Patients Receiving Berotralstat, Lana

FDA states heavy workload and limited resources prevent meeting PDUFA goal date of June 17 Agency indicates anticipated decision within four weeks KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) today announced that the U.S. Food and Drug Administration (FDA) has notified the Company that it will not meet the PDUFA goal date for the New Drug Application (NDA) for sebetralstat, the Company's investigational oral on-demand treatment for hereditary angioedema (HAE). The FDA notified the Company on June 13, 2025, that the previously disclosed June 17, 2025 PDUFA goal date will not be met due to heavy workload and limited resources. The FDA indicated that it expects to deliver a decision within

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) today announced the acceptance of six scientific abstracts at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025 taking place in Glasgow, United Kingdom from June 13–16, 2025. Details are as follows: Friday, June 13 Potential for Sebetralstat to Address Pseudo-allergic Reaction Burden Secondary to Icatibant in HAE (D1.324): Sally L. Hampton, Paul K. Audhya, Michael D. Smith, Christopher M. Yea. Results will be shared as a poster presentation from 12:00–1:00 pm BST in the Poster Zone. Saturday, June 14 Psychological Burden Associated with Injectable HAE On-Demand Treatments: A Patient and Caregiver Interview

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), today announced that the compensation committee of KalVista's board of directors granted five newly-hired employees inducement options to purchase an aggregate of 50,000 shares of KalVista common stock on June 1, 2025 as inducements material to each employee entering into employment with KalVista. The options have an exercise price that is equal to the closing price of KalVista common stock on the grant date. One-fourth of the options vest on the one-year anniversary of the vesting commencement date and the remainder vest in equal monthly installments over the next three years, in each case subject to the new employee's continued service with

–Attack progression halted in median 19.8 minutes after treatment with sebetralstat in both KONFIDENT and KONFIDENT-S trials– –Sebetralstat data demonstrated rapid relief and resolution of severe HAE attacks– KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) today announced new sebetralstat findings related to time to end of progression of hereditary angioedema (HAE) attacks, and the effectiveness of treatment of attacks considered the most debilitating by patients, mucosal attacks, and attacks that have progressed in severity after a treatment delay. These data were presented at two congresses taking place concurrently: the 14th C1-inhibitor Deficiency & Angioedema Workshop in Budapest, Hun

JMP Securities initiated coverage of KalVista Pharmaceuticals with a rating of Mkt Outperform and set a new price target of $19.00

TD Cowen initiated coverage of KalVista Pharmaceuticals with a rating of Buy and set a new price target of $30.00

BofA Securities initiated coverage of KalVista Pharmaceuticals with a rating of Buy and set a new price target of $22.00

Needham reiterated coverage of KalVista Pharmaceuticals with a rating of Buy and set a new price target of $42.00 from $48.00 previously

Needham reiterated coverage of KalVista Pharmaceuticals with a rating of Buy and set a new price target of $48.00 from $50.00 previously

SVB Leerink resumed coverage of KalVista Pharmaceuticals with a rating of Buy

Roth Capital reiterated coverage of KalVista Pharmaceuticals with a rating of Buy and set a new price target of $55.00 from $30.00 previously

Roth Capital reiterated coverage of KalVista Pharmaceuticals with a rating of Buy and set a new price target of $55.00 from $30.00 previously

Roth Capital reiterated coverage of KalVista Pharmaceuticals with a rating of Buy and set a new price target of $55.00 from $30.00 previously

HC Wainwright & Co. reiterated coverage of KalVista Pharmaceuticals with a rating of Buy and set a new price target of $48.00 from $30.00 previously

First new on-demand HAE treatment in over a decade, with potential to transform management of the disease Data demonstrated rapid symptom relief and attack resolution regardless of attack severity, location, age, or use of long-term prophylaxis, and well-established safety profile Management to host conference call today at 8:30 a.m. ET KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) today announced that the U.S. Food and Drug Administration (FDA) has approved EKTERLY® (sebetralstat), a novel plasma kallikrein inhibitor, for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged 12 years and older. EKTERLY is the first and only oral on-demand t

– Sebetralstat 300 mg achieved beginning of symptom relief in 1.6 hours – – Safety profile comparable to placebo – – On track for submission of new drug application to U.S. FDA in the first half of 2024 – – Conference call to discuss trial results today at 8:30 a.m. ET – KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced positive results from the phase 3 KONFIDENT clinical trial demonstrating statistically and clinically significant efficacy of sebetralstat as oral on-demand therapy for hereditary angioedema (HAE). KONFIDENT was the l

SC 13G/A - KalVista Pharmaceuticals, Inc. (0001348911) (Subject)

SC 13G/A - KalVista Pharmaceuticals, Inc. (0001348911) (Subject)

SC 13G - KalVista Pharmaceuticals, Inc. (0001348911) (Subject)

SC 13G - KalVista Pharmaceuticals, Inc. (0001348911) (Subject)

SC 13G/A - KalVista Pharmaceuticals, Inc. (0001348911) (Subject)

SC 13G/A - KalVista Pharmaceuticals, Inc. (0001348911) (Subject)

SC 13D/A - KalVista Pharmaceuticals, Inc. (0001348911) (Subject)

SC 13G/A - KalVista Pharmaceuticals, Inc. (0001348911) (Subject)

SC 13D/A - KalVista Pharmaceuticals, Inc. (0001348911) (Subject)

SC 13G - KalVista Pharmaceuticals, Inc. (0001348911) (Subject)

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), today announced that Jeb Ledell has joined the Company as Chief Operating Officer (COO). Mr. Ledell is an accomplished public company COO with a track record of driving operational excellence and strategic growth within the biotechnology industry. "I am pleased to welcome Jeb to KalVista at this key time in our evolution. His extensive experience in leading teams and driving efficiency within companies like ours makes him a valued addition to the team as we continue to evolve into a commercial entity," said Ben Palleiko, Chief Executive Officer of KalVista. "I am confident that his proven skills will help us to achieve our goal of delivering s

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), today announced that Laurence Reid, Ph.D., has been appointed to the Company's Board of Directors, effective immediately. Dr. Reid brings more than three decades of experience with a track record of leadership and company-building success. "I am pleased to welcome Dr. Reid, with his deep expertise in high-growth biotech companies, to the KalVista Board of Directors," said Ben Palleiko, Chief Executive Officer of KalVista. "His extensive biopharmaceutical and strategic experience will be a tremendous asset as the Company continues to progress sebetralstat towards global market approval and commercialization." "I am excited to join the KalVist

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), today announced that Brian Piekos has joined the Company as Chief Financial Officer (CFO). Mr. Piekos is an experienced public company CFO who brings a demonstrated track record of successfully leading companies across the biotechnology sector. "Brian's deep industry experience and expertise in managing financial and capital strategies makes him a strong addition to KalVista as we prepare for the commercialization of sebetralstat," said Ben Palleiko, Chief Executive Officer at KalVista. "I'm excited to welcome Brian to KalVista, as he shares our commitment to patients and a results-driven approach to business excellence." "I am excited to join

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced that William C. Fairey has been appointed to the Company's Board of Directors, effective immediately. Mr. Fairey was most recently the Chief Commercial Officer at MyoKardia, Inc., a clinical stage biopharmaceutical company, and is a business leader with significant experience building markets and launching novel therapeutics to treat specialty and rare/orphan diseases. "We welcome Bill to our Board of Directors," said Ben Palleiko, CEO of KalVista. "His experience in commercial and me

- Sebetralstat Phase 3 KONFIDENT clinical trial met all endpoints and demonstrated a favorable safety profile as first oral on-demand therapy for hereditary angioedema - - CEO transition supports ongoing evolution into commercial company - KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today provided an operational update and released financial results for the third fiscal quarter ended January 31, 2024. "This has been an exciting and busy period for KalVista, as we achieved key milestones with the release of our phase 3 KONFIDENT data and th

– Planned transition reflects evolution to commercial company with sebetralstat for HAE – – NDA filing remains on track for H1 2024; Europe and Japan filings H2 2024 – KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced that Benjamin L. Palleiko, the Company's current President, CBO and CFO, has been appointed as Chief Executive Officer and a director of the Company, effective immediately. In conjunction, Andrew Crockett has submitted his resignation as CEO and a director of the Company. This appointment is the result of a planned tr

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, announced today the appointment of Nicole Sweeny as Chief Commercial Officer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230725517894/en/KalVista Chief Commercial Officer Nicole Sweeny (Photo: Business Wire) "As KalVista prepares for our evolution into a commercial organization, we continue to strategically add individuals with deep experience in hereditary angioedema (HAE) product launches and global commercialization," said Andrew Cro

– Current Board Chairman Martin Edwards, M.D. to Retire in Planned Transition - KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced that the Board of Directors has appointed current member Brian J.G. Pereira, M.D., as Chairman, effective immediately. In conjunction, current Chairman Martin Edwards, M.D. has resigned from the Board in a planned transition concurrent with the Company's annual meeting. "We are pleased that Brian has agreed to take the Chairman role at this critical time," said Andrew Crockett, Chief Executive Officer of K

– Sebetralstat Phase 3 KONFIDENT and KVD824 Phase 2 KOMPLETE Clinical Trial Enrollment on Track – – Formal Notification Received of Sebetralstat EU Orphan Drug Status – KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today provided an operational update and released financial results for the fiscal year ended April 30, 2022. "We are pleased with the progress we have made over the last fiscal year in the development of the candidates in our oral hereditary angioedema franchise," said Andrew Crockett, Chief Executive Officer of KalVista. "We are me

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, announced today the appointment of Paul K. Audhya, MD, MBA, as Chief Medical Officer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210503005196/en/KalVista CMO Paul Audhya (Photo: Business Wire) "As we advance our oral hereditary angioedema franchise in the clinic, KalVista will be strategically growing by adding individuals with deep experience in late-stage drug development and global commercialization," said Andrew Crockett, Chief Executive O